RE: good read When I read this:
"SemBioSys is entitled to 30% ownership and profit sharing of the Joint Ventures profits for contributing select intellectual property. Tasly will contribute 100 per cent of the cost of the Joint Venture's global research, development and product commercialization. Further, Tasly will facilitate preclinical, clinical, regulatory services, manufacturing and commercial expertise, and utilize its significant sales force to commercialize the Joint Venture's products in China."
This is EXACTLY what BXI is looking for. SBS basically got BXI's dream agreement. Shareholders of BXI should be worried. SBS has the foothold into China now, BXI will be playing catch-up if they decide to enter into this market. The worry now for BXI is while they toddle around looking for what SBS already has in China, does SBS build up enough strength in the meantime to take on the North American market too?
In my eyes the two companies should have at least the same market caps now. Even adding together all of the warrants in SBS's share float, that still implies a triple from here just to catch up in market cap. Plus SBS would get a huge cash injection from the exercise of the warrants.